Kathryn Jelsma
Nurse Practitioner · Sioux Falls, SDNPI 1467919522
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 134 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Dexcom, Inc. at 26.8% of the total. Among nurse practitioner clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 134 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$592
- Medtronic$324
- Insulet Corporation$268
- Abbott$172
- Boehringer Ingelheim$143
- Novo Nordisk$104
- plus $609 from 17 others
What the payments were for
- Food & beverage$2,213100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 45 | $592 |
| Medtronic | 14 | $324 |
| Insulet Corporation | 16 | $268 |
| Abbott | 11 | $172 |
| Boehringer Ingelheim | 9 | $143 |
| Novo Nordisk | 6 | $104 |
| Sanofi-aventis U.S. LLC | 4 | $87 |
| Amgen | 4 | $76 |
| Xeris Pharmaceuticals, Inc. | 3 | $65 |
| Tandem Diabetes Care, Inc. | 3 | $57 |
| Bayer | 3 | $56 |
| Corcept Therapeutics | 2 | $42 |
| Recordati_rare_diseases_inc. | 3 | $31 |
| AstraZeneca(2 entities) | 2 | $29 |
| Chiesi USA, Inc. | 1 | $26 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Amphastar Pharmaceuticals, Inc. | 1 | $20 |
| Zealand Pharma US, Inc. | 1 | $17 |
| IBSA Pharma Inc. | 1 | $16 |
| Sequel Med Tech, LLC | 1 | $16 |
| Lilly USA, LLC | 1 | $14 |
| EUSA Pharma (US) LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$133
How this compares
$2,213 in reported general payments places this provider in the 90th percentile of 504 nurse practitioner providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 358 | $466,934 |
| MounjaroTirzepatide | 202 | $228,367 |
| Tresiba Flextouch U-200Insulin Degludec | 173 | $219,954 |
| JardianceEmpagliflozin | 143 | $151,973 |
| TrulicityDulaglutide | 85 | $101,692 |
| Tresiba Flextouch U-100Insulin Degludec | 159 | $87,363 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 45 | $73,494 |
| Novolog FlexpenInsulin Aspart | 159 | $56,555 |
| Humalog Kwikpen U-200Insulin Lispro | 20 | $52,069 |
| FarxigaDapagliflozin Propanediol | 48 | $48,362 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 12 | $35,015 |
| FiaspInsulin Aspart (Niacinamide) | 11 | $31,767 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $27,280 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $22,133 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 17 | $21,088 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $104 | $510,774407 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $14 | $346,029358 claims |
| Boehringer IngelheimJardiance | $143 | $151,973143 claims |
| AstraZenecaFarxiga | $29 | $48,36248 claims |
| Sanofi-aventis U.S. LLCLantus | $87 | $8,22665 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 504 nurse practitioner providers in South Dakota.
Other nurse practitioner in Sioux Falls
- Jamie BuschSioux Falls$60K
- Jessica SlabaSioux Falls$41K
- Christopher NelsonSioux Falls$35K
- Katherine EricsonSioux Falls$13K
- Gabrielle PriceSioux Falls$5K
- Jacqueline KelleySioux Falls$5K
- Jessica YoshinoSioux Falls$5K
- Catherine McCulleySioux Falls$5K
- Heather MitzelSioux Falls$5K
- Tiffanie VaneimerenSioux Falls$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.